About this trial
Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these group of patients. Livitol-17 consist of the 3 whole herbs and extract which has antioxidant, hepatoprotective as well as reno-protective properties. The aim of this trial is to study the efficacy of herbal supplement to improve the liver function of alcoholic liver disease subject.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Chronic alcohol intake, Identified with AUDIT(Alcohol Use Disorder Inventory Test) Questionnaire
Active alcohol use until 4 weeks prior to presentation
ALT and AST elevated >1.5 times the upper limit of normal
Over 1.5 ratio of AST to ALT
Disqualifiers
Severe alcoholic hepatitis with cirrhosis or life expectancy less than 3 months
Severe renal impairment (Glomerular filtration rate below 60 ml/min per 1.73m2)
Hepatic disorders due to cardiac causes, inherited metabolic causes, hemochromatosis and Wilson's disease
Participants with active viral hepatitis
Trial design
Single group
Treatments tested in this trial
Livitol-70
DrugLivitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
Treatment groups
Trial outcomes
Primary outcomes
Change from baseline in AST(Aspartate Aminotransferase)
The above mentioned test will be measured with panel of Liver function test at central laboratory.
Change from baseline in ALT(Alanine Aminotransferase)
The above mentioned test will be measured with panel of Liver function test at central laboratory.
Change from baseline in ALP(Alkaline Phosphatase)
The above mentioned test will be measured with panel of Liver function test at central laboratory.
Change from baseline in GGT(Gamma Glutamyl Transferase)
The above mentioned test will be measured with panel of Liver function test at central laboratory.
Secondary outcomes
Change in radiological response
The degree of fatty infiltration will be assessed by ultrasound.
Change in maddrey discriminant function(DF)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: